4 Analysts Have This to Say About ProQR Therapeutics
Portfolio Pulse from Benzinga Insights
Four analysts have provided ratings for ProQR Therapeutics (NASDAQ:PRQR) in the last quarter, with one being bullish, two somewhat bullish, and one indifferent. The average price target given by these analysts is $4.38, compared to the current price of $1.535, implying an upside. However, this average has decreased by 12.4% from the previous average price target of $5.00.
August 04, 2023 | 6:00 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Analysts' average price target for ProQR Therapeutics is $4.38, implying an upside from the current price of $1.535. However, the average target has decreased by 12.4% from the previous average of $5.00.
The average price target given by analysts suggests a potential upside for ProQR Therapeutics, which could positively impact the stock price. However, the decrease in the average target could indicate a less optimistic view of the company's future performance, which might temper the positive impact.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100